J Menopausal Med.  2018 Dec;24(3):143-149. 10.6118/jmm.2018.24.3.143.

Sharing Pathological Mechanisms of Insomnia and Osteoporosis, and a New Perspective on Safe Drug Choice

• Yi SS
• Chung SH
• Kim PS

• KMID: 2455886
• DOI: http://doi.org/10.6118/jmm.2018.24.3.143

Abstract

Lack of adequate sleep has become increasingly common in our 24/7 modern society. Reduced sleep has significant health consequences including metabolic and cardiovascular disorders, and mental problems including depression. In addition, although the increase in life expectancy has provided a dream of longevity to humans, the occurrence of osteoporosis is a big obstacle to this dream for both male and female. It is known that insomnia and bone health problems, which are very critical conditions in human life, interestingly, share a lot of pathogenesis in recent decades. Nevertheless, due to another side effects of the synthetic drugs being taken for the treatment of insomnia and osteoporosis, patients have substantial anxiety for the safety of drugs with therapeutic expectation. This review examines the pathogenesis shared by sleep and osteoporosis together and herbal medicine, which has recently been shown to be safe and efficacious in the treatment of both diseases other than synthetic drugs. We suggestions for how to treat osteoporosis. These efforts will be the first step toward enabling patients to have comfortable and safe prescriptions through a wide selection of therapeutic agents in the future.

Keyword

Herbal medicine; Osteoporosis; Safety; Sleep

MeSH Terms

Anxiety
Depression
Dreams
Female
Herbal Medicine
Humans
Life Expectancy
Longevity
Male
Osteoporosis*
Prescriptions
Sleep Initiation and Maintenance Disorders*

Reference

1. Te Lindert BHW, Itzhacki J, van der Meijden WP, Kringelbach ML, Mendoza J, Van Someren EJW. Bright environmental light ameliorates deficient subjective ‘liking’ in insomnia: an experience sampling study. Sleep. 2018; DOI: 10.1093/sleep/zsy022.

2. Passos GS, Poyares D, Santana MG, Teixeira AA, Lira FS, Youngstedt SD, et al. Exercise improves immune function, antidepressive response, and sleep quality in patients with chronic primary insomnia. Biomed Res Int. 2014; 2014:498961.

3. Fifel K, Meijer JH, Deboer T. Long-term effects of sleep deprivation on neuronal activity in four hypothalamic areas. Neurobiol Dis. 2018; 109:54–63.

4. Cizza G, Primma S, Csako G. Depression as a risk factor for osteoporosis. Trends Endocrinol Metab. 2009; 20:367–373.

5. Cizza G, Ravn P, Chrousos GP, Gold PW. Depression: a major, unrecognized risk factor for osteoporosis? Trends Endocrinol Metab. 2001; 12:198–203.

6. North American Menopause Society. Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society. Menopause. 2006; 13:340–367.

7. Sharma N, Natung T, Barooah R, Ahanthem SS. Effect of multiparity and prolonged lactation on bone mineral density. J Menopausal Med. 2016; 22:161–166.

8. Choi CJ, Choi WS, Kim CM, Lee SY, Kim KS. Risk of sarcopenia and osteoporosis in male tuberculosis survivors: Korea National Health and Nutrition Examination Survey. Sci Rep. 2017; 7:13127.

9. McCabe IC, Fedorko A, Myers MG Jr, Leinninger G, Scheller E, McCabe LR. Novel leptin receptor signaling mutants identify location and sex-dependent modulation of bone density, adiposity, and growth. J Cell Biochem. 2018; DOI: 10.1002/jcb.27726.

10. Thadani SR, Ristow B, Blackwell T, Mehra R, Stone KL, Marcus GM, et al. Relationship of bisphosphonate therapy and atrial fibrillation/flutter: Outcomes of sleep disorders in older men (MrOS Sleep) study. Chest. 2016; 149:1173–1180.

11. Schmid SM, Hallschmid M, Schultes B. The metabolic burden of sleep loss. Lancet Diabetes Endocrinol. 2015; 3:52–62.

12. Fink JE, Hackney AC, Matsumoto M, Maekawa T, Horie S. Mobility and biomechanical functions in the aging male: Testosterone and the locomotive syndrome. Aging Male. 2018; DOI: 10.1080/13685538.2018.1504914.

13. Biver E, Salliot C, Combescure C, Gossec L, Hardouin P, Legroux-Gerot I, et al. Influence of adipokines and ghrelin on bone mineral density and fracture risk: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011; 96:2703–2713.

14. Munhoz da Rocha Lemos Costa T, Costa FM, Hoffman Jonasson T, Aguiar Moreira C, Boguszewski CL, Cunha Borges JL, et al. Bone mineral density and vertebral fractures and their relationship with pulmonary dysfunction in patients with chronic obstructive pulmonary disease. Osteoporos Int. 2018; 29:2537–2543.

15. Sasaki N, Fujiwara S, Yamashita H, Ozono R, Teramen K, Kihara Y. Impact of sleep on osteoporosis: sleep quality is associated with bone stiffness index. Sleep Med. 2016; 25:73–77.

16. Davis SR, Jane F. Drugs for the treatment of menopausal symptoms. Expert Opin Pharmacother. 2010; 11:1329–1341.

17. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest. 1998; 102:274–282.

18. Braun T, Schett G. Pathways for bone loss in inflammatory disease. Curr Osteoporos Rep. 2012; DOI: 10.1007/s11914-012-0104-5.

19. Dowd JB, Goldman N, Weinstein M. Sleep duration, sleep quality, and biomarkers of inflammation in a Taiwanese population. Ann Epidemiol. 2011; 21:799–806.

20. Ferrie JE, Kivimäki M, Akbaraly TN, Singh-Manoux A, Miller MA, Gimeno D, et al. Associations between change in sleep duration and inflammation: findings on C-reactive protein and interleukin 6 in the Whitehall II Study. Am J Epidemiol. 2013; 178:956–961.

21. McLean RR. Proinflammatory cytokines and osteoporosis. Curr Osteoporos Rep. 2009; 7:134–139.

22. Tong Q, Wu W, Wu Q, Yu Y, Lv X, Wang B, et al. Sleep onset latency is related with reduced bone mineral density in elderly people with insomnia: a retrospective study. Clin Interv Aging. 2018; 13:1525–1530.

23. Pervanidou P, Chrousos GP. Stress and obesity/metabolic syndrome in childhood and adolescence. Int J Pediatr Obes. 2011; 6:Suppl 1. 21–28.

24. Yirmiya R, Goshen I, Bajayo A, Kreisel T, Feldman S, Tam J, et al. Depression induces bone loss through stimulation of the sympathetic nervous system. Proc Natl Acad Sci U S A. 2006; 103:16876–16881.

25. Gold PW. The organization of the stress system and its dysregulation in depressive illness. Mol Psychiatry. 2015; 20:32–47.

26. Eskandari F, Martinez PE, Torvik S, Phillips TM, Sternberg EM, Mistry S, et al. Low bone mass in premenopausal women with depression. Arch Intern Med. 2007; 167:2329–2336.

27. Weston CS. Posttraumatic stress disorder: a theoretical model of the hyperarousal subtype. Front Psychiatry. 2014; 5:37.

28. Kuriyama N, Inaba M, Ozaki E, Yoneda Y, Matsui D, Hashiguchi K, et al. Association between loss of bone mass due to short sleep and leptin-sympathetic nervous system activity. Arch Gerontol Geriatr. 2017; 70:201–208.

29. Sakurai T. The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat Rev Neurosci. 2007; 8:171–181.

30. Sakurai T, Mieda M. Connectomics of orexin-producing neurons: interface of systems of emotion, energy homeostasis and arousal. Trends Pharmacol Sci. 2011; 32:451–462.

31. Wei W, Motoike T, Krzeszinski JY, Jin Z, Xie XJ, Dechow PC, et al. Orexin regulates bone remodeling via a dominant positive central action and a subordinate negative peripheral action. Cell Metab. 2014; 19:927–940.

32. Allard JS, Tizabi Y, Shaffery JP, Trouth CO, Manaye K. Stereological analysis of the hypothalamic hypocretin/orexin neurons in an animal model of depression. Neuropeptides. 2004; 38:311–315.

33. Brundin L, Björkqvist M, Petersén A, Träskman-Bendz L. Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder. Eur Neuropsychopharmacol. 2007; 17:573–579.

34. Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell. 1999; 98:437–451.

35. Hara J, Beuckmann CT, Nambu T, Willie JT, Chemelli RM, Sinton CM, et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron. 2001; 30:345–354.

36. Sellayah D, Bharaj P, Sikder D. Orexin is required for brown adipose tissue development, differentiation, and function. Cell Metab. 2011; 14:478–490.

37. Brisbare-Roch C, Dingemanse J, Koberstein R, Hoever P, Aissaoui H, Flores S, et al. Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med. 2007; 13:150–155.

38. Funato H, Tsai AL, Willie JT, Kisanuki Y, Williams SC, Sakurai T, et al. Enhanced orexin receptor-2 signaling prevents diet-induced obesity and improves leptin sensitivity. Cell Metab. 2009; 9:64–76.

39. Kotz C, Nixon J, Butterick T, Perez-Leighton C, Teske J, Billington C. Brain orexin promotes obesity resistance. Ann N Y Acad Sci. 2012; 1264:72–86.

40. Lago F, Gonzalez-Juanatey JR, Casanueva FF, Gómez-Reino J, Dieguez C, Gualillo O. Ghrelin, the same peptide for different functions: player or bystander? Vitam Horm. 2005; 71:405–432.

41. Nouh O, Abd Elfattah MM, Hassouna AA. Association between ghrelin levels and BMD: a cross sectional trial. Gynecol Endocrinol. 2012; 28:570–572.

42. Kim SW, Her SJ, Park SJ, Kim D, Park KS, Lee HK, et al. Ghrelin stimulates proliferation and differentiation and inhibits apoptosis in osteoblastic MC3T3-E1 cells. Bone. 2005; 37:359–369.

43. Delhanty PJ, van der Eerden BC, van der Velde M, Gauna C, Pols HA, Jahr H, et al. Ghrelin and unacylated ghrelin stimulate human osteoblast growth via mitogen-activated protein kinase (MAPK)/phosphoinositide 3-kinase (PI3K) pathways in the absence of GHS-R1a. J Endocrinol. 2006; 188:37–47.

44. Fukushima N, Hanada R, Teranishi H, Fukue Y, Tachibana T, Ishikawa H, et al. Ghrelin directly regulates bone formation. J Bone Miner Res. 2005; 20:790–798.

45. Arble DM, Vitaterna MH, Turek FW. Rhythmic leptin is required for weight gain from circadian desynchronized feeding in the mouse. PLoS One. 2011; 6:e25079.

46. Scheer FA, Hilton MF, Mantzoros CS, Shea SA. Adverse metabolic and cardiovascular consequences of circadian misalignment. Proc Natl Acad Sci U S A. 2009; 106:4453–4458.

47. Baranowska B, Baranowska-Bik A, Bik W, Martynska L. The role of leptin and orexins in the dysfunction of hypothalamo-pituitary-gonadal regulation and in the mechanism of hyperactivity in patients with anorexia nervosa. Neuro Endocrinol Lett. 2008; 29:37–40.

48. Paredes SD, Barriga C, Reiter RJ, Rodriguez AB. Assessment of the potential role of tryptophan as the precursor of serotonin and melatonin for the aged sleep-wake cycle and immune function: Streptopelia risoria as a model. Int J Tryptophan Res. 2009; 2:23–36.

49. Frase L, Nissen C, Riemann D, Spiegelhalder K. Making sleep easier: pharmacological interventions for insomnia. Expert Opin Pharmacother. 2018; 19:1465–1473.

50. Lee S, Le NH, Kang D. Melatonin alleviates oxidative stress-inhibited osteogenesis of human bone marrow-derived mesenchymal stem cells through AMPK activation. Int J Med Sci. 2018; 15:1083–1091.

51. Xu L, Zhang L, Wang Z, Li C, Li S, Li L, et al. Melatonin suppresses estrogen deficiency-induced osteoporosis and promotes osteoblastogenesis by inactivating the NLRP3 inflammasome. Calcif Tissue Int. 2018; 103:400–410.

52. Um MJ, Cho EA, Jung H. Combination therapy of raloxifene and alendronate for treatment of osteoporosis in elderly women. J Menopausal Med. 2017; 23:56–62.

53. Jung M. Zolpidem overdose: A dilemma in mental health. Health Care Manag (Frederick). 2018; 37:86–89.

54. Kwon CY, Lee B, Chung SY, Kim JW, Kim SH. Oriental herbal medicine for insomnia in the elderly with hypertension: A systematic review protocol. Medicine (Baltimore). 2018; 97:e12200.

55. Kim M, Lim HS, Lee HH, Kim TH. Role identification of Passiflora incarnata linnaeus: A mini review. J Menopausal Med. 2017; 23:156–159.

56. Singh A, Zhao K. Treatment of insomnia with traditional Chinese herbal medicine. Int Rev Neurobiol. 2017; 135:97–115.

57. Ahmad N, Chillara R, Kushwaha P, Khedgikar V, Karvande A, Choudhary D, et al. Evaluation of anti-osteoporotic activity of butanolic fraction from Passiflora foetida in ovariectomy-induced bone loss in mice. Biomed Pharmacother. 2017; 88:804–813.

58. Ngan A, Conduit R. A double-blind, placebo-controlled investigation of the effects of Passiflora incarnata (passion-flower) herbal tea on subjective sleep quality. Phytother Res. 2011; 25:1153–1159.

59. Jawna-Zboińska K, Blecharz-Klin K, Joniec-Maciejak I, Wawer A, Pyrzanowska J, Piechal A, et al. Passiflora incarnata L. improves spatial memory, reduces stress, and affects neurotransmission in rats. Phytother Res. 2016; 30:781–789.

60. Aoyagi N, Kimura R, Murata T. Studies on passiflora incarnata dry extract. I. Isolation of maltol and pharmacological action of maltol and ethyl maltol. Chem Pharm Bull (Tokyo). 1974; 22:1008–1013.